reviewed april 2026|next review october 2026|88 physicians psi has verified|662 published studies
CJC-1295 without DAC (Mod GRF 1-29)
CJC-1295 without DAC (Modified GRF 1-29, Mod GRF 1-29) is a shorter-acting GHRH analog with a 30-minute half-life that stimulates pulsatile growth hormone release, commonly combined with ipamorelin in clinical practice protocols for GH optimization.
Evidence landscape: 662 published studies
Evidence is shared with the CJC-1295 parent compound. Independent clinical studies for the no-DAC variant are limited.
- 18 Human
- 126 Animal
- 56 Reviews
- 462 Other research
The no-DAC version has a half-life of approximately 30 minutes (vs days for CJC-1295 DAC). This produces pulsatile GH release that more closely mimics natural physiology.
Widely used in functional medicine and anti-aging protocols, typically combined with ipamorelin. This combination is the most common peptide pairing in GH optimization.
The GHRH mechanism is well-characterized through the parent CJC-1295 compound. Independent clinical trial data specifically for the no-DAC variant is limited.
PSI Assessment
CJC-1295 without DAC is the shorter-acting version of CJC-1295, preferred by many clinicians because it produces growth hormone release in pulses rather than sustained elevation. The distinction matters because the body naturally releases GH in bursts, not continuously. A 30-minute half-life means the pituitary receives a signal, releases GH, and the signal clears. The most common clinical practice protocol combines it with ipamorelin (a GHRP) for synergistic GH stimulation through two different pathways. The GHRH pharmacology is well-understood, but independent clinical trial data for this specific variant is limited.
The pulsatile version of CJC-1295. 30-minute half-life produces more physiological GH release patterns. The most common peptide combination in GH optimization is CJC-1295 no-DAC + ipamorelin.
Modified GRF(1-29) contains the first 29 amino acids of GHRH with four amino acid substitutions at positions 2, 8, 15, and 27 for improved metabolic stability. Unlike CJC-1295 DAC, it does not bind albumin and clears from the system in approximately 30 minutes. This produces acute GH pulses rather than sustained elevation. The pharmacological synergy with GH secretagogues (particularly ipamorelin) is the primary clinical rationale for the no-DAC formulation: pulsatile GHRH stimulation combined with pulsatile GHRP stimulation for amplified but physiological GH release.
What the evidence supports
GHRH receptor binding and growth hormone stimulation are pharmacologically confirmed. The shorter half-life (approximately 30 minutes vs days for DAC version) produces more physiological pulsatile GH release patterns. Synergistic effects with GHRP-class peptides like ipamorelin are well-documented in clinical practice.
What is not yet established
Independent clinical trial data specifically for this variant (most published research references the parent CJC-1295 compound). Clinical superiority of the no-DAC formulation over the DAC version. Whether pulsatile GH release patterns produce meaningfully different clinical outcomes. Long-term safety data from controlled studies.
Research Evidence
The findings below cover the pulsatile GH release mechanism, the comparison with the DAC version, and the ipamorelin combination rationale.
Evidence by condition
Evidence dimensions for CJC-1295 no-DAC. GH stimulation is well-characterized. Clinical outcome data is primarily from the parent compound.
| Condition | Mechanism | Animal evidence | Human evidence | Replication |
|---|---|---|---|---|
| Growth Hormone Optimization | ||||
| Anti-Aging Protocols |
Modified GRF(1-29) binds GHRH receptors on pituitary somatotrophs and stimulates acute GH release. The 30-minute half-life produces pulsatile GH patterns rather than sustained elevation.
The pulsatile pattern is considered more physiological. Whether this translates to clinically meaningful differences compared to the DAC version is not established.
Combination with ipamorelin (a GHRP) produces synergistic GH release through complementary pathways: GHRH receptor stimulation plus ghrelin receptor stimulation.
The two pathways are mechanistically independent, supporting the combination rationale. This is the most widely used peptide combination in functional medicine GH protocols.
Most published pharmacology data references the parent CJC-1295 compound. Independent clinical trial data specifically for the no-DAC variant is limited to pharmacokinetic characterization.
The evidence base relies on shared GHRH pharmacology rather than independent clinical validation of this specific formulation.
18 Human|126 Animal|56 Reviews
View all 662 indexed studiesHow CJC-1295 without DAC (Mod GRF 1-29) Works
CJC-1295 without DAC (Mod GRF 1-29) is a modified GHRH(1-29) analog with four amino acid substitutions for metabolic stability that stimulates pulsatile growth hormone release through GHRH receptor agonism.
CJC-1295 no-DAC sends a signal to the pituitary gland to release growth hormone in a burst, then clears from the system quickly. This mimics the natural pulsatile pattern of GH release rather than continuous elevation. Often combined with Ipamorelin for synergistic GH release.
For a more detailed view of the biology, here is what researchers have observed at the molecular level.
Modified GRF(1-29) with amino acid substitutions at positions 2 (D-Ala), 8 (Gln), 15 (Ala), and 27 (Leu) for improved metabolic stability against DPP-IV (dipeptidyl peptidase IV) degradation. Binds GHRH receptor on anterior pituitary somatotrophs, activating adenylyl cyclase via Gs protein coupling and increasing cAMP to stimulate GH gene transcription and secretion. Half-life approximately 30 minutes (vs 6-8 days for DAC version). Does not bind albumin. Often combined with ghrelin-mimetic peptides for complementary GH axis stimulation.
What is CJC-1295 without DAC (Mod GRF 1-29) being studied for?
Researchers are studying CJC-1295 without DAC (Mod GRF 1-29) across several health conditions. Each condition below is labeled with the strength of evidence that exists for that specific use, not for CJC-1295 without DAC (Mod GRF 1-29) overall. This means a compound can have human studies for one condition but only animal data for another.
Growth Hormone Optimization
·Animal StudiesStimulates pulsatile GH release via GHRH receptor agonism. Widely used in functional medicine protocols, typically combined with ipamorelin.
Limitations: Independent clinical trial data is limited. Most published research references the parent CJC-1295 compound. Long-term outcomes of GH optimization protocols are not established in controlled studies.
Anti-Aging Protocols
·Animal StudiesUsed in GH optimization protocols for age-related GH decline. The combination with ipamorelin is the most common peptide pairing in this context.
Limitations: No controlled clinical trials demonstrate anti-aging benefits specifically from this formulation. The clinical practice evidence is observational.
Safety and Regulatory Status
FDA Status: Not FDA-approved for any indication.
Availability: Available through specialty pharmacies, where a licensed pharmacist prepares a medicine from ingredients for an individual patient, in some jurisdictions. Regulatory status varies.
Class context: Side effects include flushing, headache, dizziness, and injection site reactions. Generally well tolerated in clinical practice protocols.
Generally well tolerated. Common side effects include flushing, headache, and injection site reactions. Not FDA-approved. Long-term safety data from controlled studies is not available.
Peptide Structure
Technical molecular data for researchers and clinicians.
Questions and Comparisons
Questions the evidence raises for a CJC-1295 without DAC (Mod GRF 1-29) discussion.
Comparison and Related Research
CJC-1295 no-DAC is most often compared with the DAC version and with ipamorelin (its most common combination partner).
Head-to-head comparisons
Full research comparisons covering CJC-1295 without DAC (Mod GRF 1-29) and another peptide side by side.
CJC-1295 without DAC (Mod GRF 1-29) vs Sermorelin
Evidence-based comparison of Sermorelin and CJC-1295 No DAC (Mod GRF 1-29). Pharmacokinetic similarity, branding clarity, regulatory history, and sourcing differences.
View full comparisonRelated compounds
Frequently Asked Questions
References
Each citation links to the original study on PubMed, the U.S. National Library of Medicine database.
- 1.Characterized the pharmacology of the CJC-1295 peptide backbone, demonstrating sustained GH and IGF-1 stimulation in healthy adults. The no-DAC version shares the same receptor-binding sequence but with a shorter half-life producing pulsatile release.Teichman SL et al., 2006 in J Clin Endocrinol Metab. View on PubMed
- 2.Demonstrated that GHRH receptor agonism produces GH release in the context of modified GRF pharmacology, supporting the mechanism by which Mod GRF 1-29 (no-DAC) stimulates pulsatile GH secretion.Ionescu M & Frohman LA, 2006 in Growth Horm IGF Res. View on PubMed
- 3.Showed that repeated GHRH administration can restore the blunted GH response that occurs with aging, supporting the rationale for using GHRH analogs like Mod GRF 1-29 in age-related GH optimization.Iovino M et al., 1999 in J Endocrinol Invest. View on PubMed
- 4.Characterized the importance of pulsatile GH secretion patterns throughout life, providing the physiological basis for why shorter-acting GHRH analogs like Mod GRF 1-29 may better mimic natural GH release compared to sustained-release formulations.Veldhuis JD et al., 2005 in J Clin Endocrinol Metab. View on PubMed
Medical Disclaimer
This content is for educational and informational purposes only and does not constitute medical advice. The information presented reflects published research as indexed by PSI and should not be used to make treatment decisions. Always consult a qualified healthcare provider before starting, stopping, or modifying any treatment.